Cryolife, Inc. (CRY) Dividend History

CryoLife, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive. CryoLife, Inc. incorporated in 1984 in Florida, was the first biomedical company to specialize in the ultra-low temperature preservation of human heart valves used for cardiac reconstruction, primarily in children born with heart defects. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve® SG pulmonary human heart valve and the CryoPatch® SG pulmonary cardiac patch tissue, both processed using CryoLife’s proprietary SynerGraft® technology. CryoLife’s medical devices consist of surgical adhesives, sealants, and hemostats including BioGlue® Surgical Adhesive, PerClot®, which the Company began distributing for Starch Medical, Inc. in October 2010, as well as On-X® Heart Valves, which they acquired in 2016, and aortic stent grafts manufactured by JOTEC® GmbH, which they acquired in 2017. In 2019, CryoLife entered a distribution agreement with Endospan.The agreement gives CryoLife exclusive European distribution rights to Nexus, an endovascular stent graft system approved for the repair of aneurysms and dissections in the aortic arch.

Last update 01/26/2022